Trial Profile
Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs IM 23 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Beijing Immunochina Medical Science and Technology
- 18 Jan 2023 Status changed from recruiting to completed.
- 20 Jul 2018 New trial record